Sacha I. Rothschild

First-line durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

P. Froesch, M. Früh, Katrin Gysel, 2024, European Journal of Cancer.

Focusing on cancer patients' intentions to use psychooncological support: A longitudinal, mixed‐methods study

S. Hunziker, C. Rochlitz, D. Zwahlen, 2018, Psycho-oncology.

Patient-reported outcomes in CodeBreak 200: Sotorasib versus docetaxel for previously treated advanced NSCLC with KRAS G12C mutation

F. Bozorgmehr, C. Obiozor, Normand Blais, 2024, Lung Cancer.